TLSI TriSalus Life Sciences, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1826667 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.4%
TTM net income YoY33.7%
TTM EPS YoY80.7%
Revenue 3-yr CAGR42.5%
Net income 3-yr CAGR—
Margins
Gross margin86.5%
Operating margin-63.0%
Net margin-56.6%
FCF margin-53.3%
EBITDA margin-61.8%
Returns
ROE—
ROA-55.8%
ROIC (approx.)—
Asset turnover0.99x
Leverage & solvency
Liabilities / assets98.8%
Debt / equity47.60x
Current ratio4.22x
Interest coverage-4.92x
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $45.15M | $29.43M | $18.51M | $12.40M | — |
| Cost of revenue | $6.96M | $4.10M | $2.60M | $2.26M | — |
| Gross profit | $38.19M | $25.33M | $15.91M | $10.14M | — |
| R&D expense | $14.96M | $17.69M | $29.84M | $21.36M | — |
| SG&A expense | $21.46M | $17.97M | $23.51M | $12.48M | $3.04M |
| Operating income | -$26.95M | -$36.16M | -$54.48M | -$36.44M | -$3.04M |
| Interest expense | $5.54M | $3.09M | $16,000 | $1,000 | — |
| Pretax income | -$39.22M | -$30.04M | -$59.35M | -$47.18M | $4.77M |
| Income tax | $7,000 | $6,000 | $9,000 | $9,000 | $0 |
| Net income | -$39.23M | -$30.05M | -$59.36M | -$47.19M | $4.77M |
| EBITDA | -$26.32M | -$35.42M | -$53.79M | -$36.04M | — |
| EPS (basic) | -1.84 | -1.31 | -6.77 | -161.55 | — |
| EPS (diluted) | -1.84 | -1.31 | -6.77 | -161.55 | — |
| Weighted avg. shares (diluted) | 37.90M | 25.33M | 9.40M | 309,609 | — |
| Balance sheet | |||||
| Cash & equivalents | $20.44M | $8.88M | $12.13M | $9.66M | $30.30M |
| Receivables | $6.56M | $5.09M | $3.55M | $1.56M | — |
| Inventory | $3.08M | $4.05M | $2.54M | $1.47M | — |
| Current assets | $32.24M | $20.67M | $20.86M | $17.21M | $525,884 |
| PP&E, net | $1.81M | $1.67M | $2.09M | $2.23M | — |
| Intangibles | — | — | $0 | $802,000 | — |
| Total assets | $35.33M | $23.97M | $24.60M | $22.00M | $250.53M |
| Current liabilities | $11.50M | $10.23M | $14.69M | $32.36M | $1.60M |
| Long-term debt | $33.05M | $22.08M | $0 | — | — |
| Total debt | $33.05M | $22.08M | $0 | — | — |
| Total liabilities | $69.19M | $49.87M | $51.66M | $34.32M | $17.25M |
| Shareholders' equity | -$33.86M | -$25.89M | -$27.07M | -$177.13M | -$129.60M |
| Net debt | $12.61M | $13.21M | -$12.13M | — | — |
| Shares outstanding | 50.00M | 31.28M | 26.41M | 347,926 | — |
| Cash flow statement | |||||
| Operating cash flow | -$18.01M | -$40.84M | -$50.58M | -$32.31M | -$1.74M |
| Capital expenditure | $918,000 | $345,000 | $588,000 | $655,000 | — |
| Free cash flow | -$18.93M | -$41.19M | -$51.17M | -$32.97M | — |
| Investing cash flow | -$838,000 | -$345,000 | -$1.59M | -$1.79M | $60,000 |
| Financing cash flow | $30.76M | $37.94M | $54.63M | $13.46M | $544,000 |
| Depreciation & amortization | $626,000 | $744,000 | $684,000 | $398,000 | — |
| Stock-based compensation | $9.13M | $5.44M | $1.40M | $368,000 | — |
| Share buybacks | — | — | — | $232.37M | — |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.